LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

Orgenesis Provides Business Update for the Third Quarter of 2023

November 13, 2023 | Last Trade: US$2.10 0.01 -0.47

GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023.

Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercial launch of our POCare Platform through Octomera, building out a decentralized network and infrastructure to deliver these advanced therapeutic services that are critically needed by the medical community. At the same time, we are focused on growing our POCare Network of hospitals and healthcare providers across the U.S., Europe, the Middle East and other regions, where advanced cell and gene therapies can be rapidly scaled up to meet growing demand across the industry. We believe the Company is well positioned to support the clinical and commercial advancement of these therapies for years to come.”

“Recently, we expanded our partnership with California Davis (UC Davis) through California Institute of Regenerative Medicine (CIRM) grant funding to streamline production of CGT products across California. We believe that our platform will benefit patients in the state by accelerating access to CGT products in an affordable format at the point of care, which, in turn, are expected to lower costs, expand capacity, and enhance distribution. We remain on track to deploy our Octomera Mobile Processing Units & Labs (OMPULs) for production at UC Davis and other healthcare universities within the State of California in the upcoming year. Moreover, Octomera entered into an agreement with CGT Global to utilize its extensive network of U.S. clinics to help accelerate research and clinical trials, aimed at rapidly commercializing CGT products across the United States and potentially bringing these life-saving therapies to larger numbers of patients in need.”

Ms. Caplan continued, “In addition to our POCare Services platform, we are advancing our therapeutic pipeline, which now spans multiple clinical programs in the field of immuno-oncology, anti-viral, metabolic/autoimmune diseases, and tissue regeneration. Our cost-efficient strategy includes leveraging government grants and funding from regional partners, as well finding the optimal licensing and marketing partners for some of the more advanced products in our pipeline. Importantly, we believe we have built a highly scalable business model.”

The complete financial results for the third quarter of 2023 are available on the Company’s website in the Company’s Form 10-Q, which has been filed with the Securities and Exchange Commission. It is important to note that the Company deconsolidated Octomera on June 30, 2023, though the Company still holds a 75% stake in the business. Accordingly, the results of Octomera’s operations subsequent to June 30, 2023, are not reflected in the Company’s consolidated financial statements. Octomera itself recognized revenue of $2.7 million, reflecting a temporary delay in cell processing and cell process development contracts, which are expected to be completed in the fourth quarter of 2023 and first quarter of 2024. The Company also notes that as a result of the deconsolidation of Octomera, the assets and liabilities of Octomera are not included on the Company’s balance sheet and statements of comprehensive loss for the period ended September 30, 2023.

About Orgenesis

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. Additional information about the Company is available at: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
This email address is being protected from spambots. You need JavaScript enabled to view it.

Communications contact for Orgenesis
IB Communications
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.

ORGENESIS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. Dollars, in thousands)
(Unaudited)

  As of
  September 30,
2023
   December 31,
2022
 
Assets       
        
CURRENT ASSETS:       
Cash and cash equivalents$55  $5,311 
Restricted cash 734   1,058 
Accounts receivable, net 71   36,183 
Prepaid expenses and other receivables 4,031   958 
Receivables from related parties 1,052   - 
Convertible loan to related party 2,799   2,688 
Inventory 34   120 
Total current assets 8,776   46,318 
        
NON-CURRENT ASSETS:       
Deposits$40  $331 
Equity investees 22,509   39 
Loans to associates 93   96 
Property, plant and equipment, net 1,503   22,834 
Intangible assets, net 7,528   9,694 
Operating lease right-of-use assets 431   2,304 
Goodwill 3,703   8,187 
Deferred tax -   103 
Other assets 716   1,022 
Total non-current assets 36,523   44,610 
TOTAL ASSETS$45,299  $90,928 

ORGENESIS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. Dollars, in thousands)
(Unaudited)

  As of
  September 30,
2023
  December 31,
2022
Liabilities and Equity     
      
CURRENT LIABILITIES:     
Accounts payable$5,459  $4,429 
Accounts payable related parties 132   - 
Accrued expenses and other payables 1,895   2,578 
Income tax payable 307   289 
Employees and related payables 807   1,860 
Other payables related parties 999   - 
Advance payments on account of grant 1,376   1,578 
Short-term loans 430   - 
Contract liabilities 120   70 
Current maturities of finance leases 17   60 
Current maturities of operating leases 220   542 
Short-term and current maturities of convertible loans 2,540   4,504 
Total current liabilities 14,302   15,910 
      
LONG-TERM LIABILITIES:     
Non-current operating leases$140  $1,728 
Convertible loans 18,394   13,343 
Retirement benefits obligation -   163 
Long-term debt and finance leases 8   95 
Advance payments on account of grant -   144 
Other long-term liabilities 58   271 
Total long-term liabilities 18,600   15,744 
TOTAL LIABILITIES 32,902   31,654 
      
REDEEMABLE NON-CONTROLLING INTEREST$-  $30,203 
      
EQUITY:
Common stock of $0.0001 par value: Authorized at September 30, 2023 and December 31, 2022: 145,833,334 shares; Issued at September 30, 2023 and December 31, 2022: 30,753,374 and 25,832,322 shares, respectively; Outstanding at September 30, 2023 and December 31, 2022: 30,466,807 and 25,545,755 shares, respectively
 3   3 
Additional paid-in capital 155,819   150,355 
Accumulated other comprehensive income (loss) 71   (270)
Treasury stock 286,567 shares as of September 30, 2023 and December 31, 2022 (1,266)  (1,266)
Accumulated deficit (142,230)  (121,261)
Equity attributable to Orgenesis Inc. 12,397   27,561 
Non-controlling interest -   1,510 
Total equity 12,397   29,071 
TOTAL LIABILITIES REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY$45,299  $90,928 
        

ORGENESIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(U.S. Dollars, in thousands, except share and per share amounts)
(Unaudited)

 Three Months Ended Nine Months Ended  
  September 30,
2023
   September 30,
2022
   September 30,
2023
   September 30,
2022
 
Revenues$110  $7,841  $14,129  $21,117 
Revenues from related party -   147   -   1,284 
Total revenues 110   7,988   14,129   22,401 
Cost of revenues 139   983   6,093   2,760 
Gross profit (loss) (29)  7,005   8,036   19,641 
Cost of development services and research and development expenses 808   3,683   7,616   18,172 
Amortization of intangible assets 153   225   568   686 
Selling, general and administrative expenses 1,245   3,104   8,621   8,758 
Operating loss 2,235   7   8,769   7,975 
Other loss (income), net (2)  2   (4)  (6)
Loss from extinguishment in connection with convertible loan -   -   283   - 
Financial expenses, net 508   1,100   1,807   1,702 
Profit from deconsolidation of Octomera (see note 3) -   -   (411)  - 
Share in net loss of associated companies 9,518   274   9,517   1,189 
Loss before income taxes 12,259   1,383   19,961   10,860 
Tax expenses 394   25   614   37 
Net loss 12,653   1,408   20,575   10,897 
Net income (loss) attributable to non-controlling interests (including redeemable) -   (52)  394   (105)
Net loss attributable to Orgenesis Inc.$12,653  $1,356  $20,969  $10,792 
            
Loss per share:           
Basic and diluted$0.43  $0.05  $0.75  $0.43 
            
Weighted average number of shares used in computation of Basic and Diluted loss per share:           
Basic and diluted 29,162,459   25,403,907   27,933,067   24,944,814 
            
Comprehensive loss:           
Net loss$12,653  $1,408  $20,575  $10,897 
Other comprehensive loss (income) - translation adjustments (9)  556   43   1,033 
Release of translation adjustment due to deconsolidation of Octomera -   -   (384)  - 
Comprehensive loss 12,644   1,964   20,234   11,930 
Comprehensive income (loss) attributed to non-controlling interests -   (52)  394   (105)
Comprehensive loss attributed to Orgenesis Inc.$12,644  $1,912  $20,628  $11,825 
                

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB